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Allan-Herndon-Dudley syndrome is a rare disease caused by inactivating mutations
in the SLC16A2 gene, which encodes the monocarboxylate transporter 8 (MCT8),
a transmembrane transporter specific for thyroid hormones (T3 and T4). Lack of
MCT8 function produces serious neurological disturbances, most likely due to impaired
transport of thyroid hormones across brain barriers during development resulting in
severe brain hypothyroidism. Patients also suffer from thyrotoxicity in other organs
due to the presence of a high concentration of T3 in the serum. An effective
therapeutic strategy should restore thyroid hormone serum levels (both T3 and T4)
and should address MCT8 transporter deficiency in brain barriers and neural cells, to
enable the access of thyroid hormones to target neural cells. Unfortunately, targeted
therapeutic options are currently scarce and their effect is limited to an improvement
in the thyrotoxic state, with no sign of any neurological improvement. The use of
thyroid hormone analogs such as TRIAC, DITPA, or sobetirome, that do not require
MCT8 to cross cell membranes and whose controlled thyromimetic activity could
potentially restore the normal function of the affected organs, are being explored to
improve the cerebral availability of these analogs. Other strategies aiming to restore
the transport of THs through MCT8 at the brain barriers and the cellular membranes
include gene replacement therapy and the use of pharmacological chaperones. The
design of an appropriate therapeutic strategy in combination with an early diagnosis
(at prenatal stages), will be key aspects to improve the devastating alterations present
in these patients.
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INTRODUCTION
Thyroid hormones (THs; T4 or thyroxine and T3 or triiodothyronine) are essential for the
development and function of the CNS. An insufficient supply of THs during development can
hinder essential processes such as neurogenesis, cell migration, synaptogenesis or myelinization.
These neurological alterations range from very mild to very severe, and can be even irreversible,
depending on the time and duration of the hormonal deficiency.
THs are synthesized in the thyroid gland, mostly as T4, and released by follicular cells to
the circulation, reaching the different target tissues. Both genomic and non-genomic actions of
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THs have been described. The latter are carried out in the
cytoplasm or plasma membrane by binding to receptors such
as integrin αvβ3 (Davis et al., 2016). On the other hand, in the
genomic actions T3 binds to nuclear receptors (TR), regulating
the transcription of target genes. The main isoforms of these
TR are TRα1, TRα2, TRβ1, and TRβ2, which mediate different
actions and whose expression varies throughout ontogeny and
different tissues. The amount of the nuclear active hormone T3
is mainly regulated locally in the target tissues by the action
of different deiodinase enzymes which activate (converting T4
into T3) or inactivate (deiodinating T4 and T3 into inactive
metabolites) THs.
THs use transporter proteins located in cell membranes to
reach the inside the cells (Hennemann et al., 2001). Some of
the major transporters of THs include the monocarboxylate
transporter 8 (MCT8), MCT10 and the solute carrier organic
anion transporter 1C1 (OATP1C1), but only MCT8 has been
identified as being specific to transport THs. MCT8 is encoded by
the SLC16A2 gene (Friesema et al., 2003) and the mutations that
cause the inactivation of this transporter result in a rare X-linked
disease known as Allan-Herndon-Dudley Syndrome (AHDS or
MCT8 deficiency). AHDS (ORPHA:59) is an ultra-rare disorder
with an estimated prevalence lower than 1 case per million.
Orphanet suggested that 320 patients had been diagnosed within
more than 130 families but these numbers are prone to raise given
the increasing access to new generation sequencing technologies
and the expanding spectrum of severity attributed to the disease
(Remerand et al., 2019).
AHDS was described in 1944 (Allan et al., 1944) but its
association to mutations in the SLC16A2 gene was established
in 2004 (Dumitrescu et al., 2004; Friesema et al., 2004). AHDS
patients have a characteristic thyroid profile with elevated plasma
T3 levels (peripheral hyperthyroidism), low T4 and normal or
slightly elevated TSH with a free T3/T4 ratio greater than 0.75
(Dumitrescu et al., 2004; Friesema et al., 2004; Groeneweg et al.,
2019; Remerand et al., 2019).
In addition, the phenotype of AHDS is characterized by severe
paraparesis with hypotonia (with poor cephalic control being
an early symptom), bradykinesia, spasticity and extrapyramidal
manifestations (dystonia or dystonia with choreoathetosis)
and moderate to severe intellectual disability with absence of
language, associated with low weight and/or low muscle mass and
in some cases, epilepsy (Remerand et al., 2019). In recent years,
the increasing knowledge about this condition have promoted a
growing number of patients that have defined a much broader
phenotype, with the appearance of milder forms with motor
and cognitive disability of lesser severity (Masnada et al., 2019;
Remerand et al., 2019).
These alterations occur as a consequence of two phenomena.
On the one hand, the excess of T3 in serum produces
peripheral hyperthyroidism with muscle thyrotoxicosis that
causes a generalized loss of muscle volume. On the other hand,
the absence of MCT8 impairs the effective transport of THs to
the CNS, most probably due to the lack of functional MCT8
in brain barriers (Ceballos et al., 2009; Iwayama et al., 2016;
Vatine et al., 2017) leading to brain hypothyroidism (Dumitrescu
et al., 2006; Trajkovic et al., 2007; López-Espíndola et al., 2014).
Indeed, brain tissue necropsies of MCT8-deficient patients
have revealed alterations compatible with brain hypothyroidism
with anomalies in neuronal differentiation, myelinization and
synaptogenesis present already from prenatal stages (López-
Espíndola et al., 2014). Consistent with this, MCT8 has been
found to be very abundant at the brain barriers in the human
fetal brain (Wirth et al., 2009; López-Espíndola et al., 2019;
Wilpert et al., 2020).
The rapid diagnosis is a key factor for the patients’
wellbeing. For instance, unlike other similar diseases, there is a
marked prevalence of respiratory problems and kyphoscoliosis,
so intensive monitoring and an adequate care is important
to improve the survival and quality of life of patients.
Moreover, due to the fact that brain alterations start during
development, an early treatment, including prenatal treatment,
takes special importance. Currently, targeted therapies to
improve the neurological picture of patients are not available.
As MCT8-deficient patients suffer from brain hypothyroidism in
combination with peripheral hyperthyroidism, the design of an
effective treatment is challenging. The aim of this manuscript is to
critically review therapeutic approaches attempted so far both at
the clinical level in patients and at the preclinical level in models
of the disease to contribute to the development of future solutions
for AHDS patients (summarized in Table 1).
MURINE MODELS OF THE DISEASE
The development of targeted therapies in rare diseases depends
on the availability of good animal models, both to unravel the
mechanisms of disease and to carry out preclinical studies to
evaluate therapeutic strategies. In the case of MCT8 deficiency,
most of the knowledge about the mechanisms underlying the
disease as well as the preclinical studies considered so far has
arisen from using murine models of the syndrome. However,
it has not been straightforward to obtain a suitable model and
there is still ongoing work focused on the characterization of
different animal models.
Initially, mice deficient of the MCT8 transporter (Mct8KO
mice) were proposed as a disease model. Although these mice
showed a thyroid profile similar to that of the patients and
relatively low levels of T3 in different brain areas (Dumitrescu
et al., 2006; Trajkovic et al., 2007), brain histopathology studies
did not reveal major defects and only subtle behavioral changes
were found (Wirth et al., 2009). It was therefore suggested
that these animals present some compensatory mechanism that
prevents neurological damage. This compensatory mechanism is
due to the complementary action of two proteins: the organic
anion transporter OATP1C1 and the deiodinase type 2 (DIO2)
enzyme. OATP1C1 transporter is codified by the Slco1c1 gene, it
transports mainly T4 and is expressed abundantly in rodent brain
barriers, but to a much lesser extent in humans (Roberts et al.,
2008; López-Espíndola et al., 2019). The entry of T4 to the brain
through this transporter and the subsequent action of DIO2,
which converts T4 into T3 in astrocytes and whose expression
is increased in these mice, would provide a sufficient amount
of the nuclear active hormone T3 in the mouse brain, exerting
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TABLE 1 | Summary of the existing clinical and preclinical therapeutic approaches for AHDS.
Effects on Effects on Effects on Effects on
Treatment Model serum TSH serum T4 serum T3 brain References
TH replacement
therapies
LT4 Human ↓ ↑ ↑ Not observed Namba et al., 2008;
Papadimitriou et al., 2008
LT4 + T3 Human ↓ ↑ ↑ Not observed Biebermann et al., 2005;
Zung et al., 2011
LT4 + PTU Human ↓ ↑ ↓ Not observed Wemeau et al., 2008;
Visser et al., 2013
TH analogs
treatments
DITPA Zebrafish N/R N/R N/R Prevents
hypomyelination
Zada et al., 2014, 2016
Mouse ↓ ↓ ↓ Only at high doses
(0.01 mg/g BW)
Di Cosmo et al., 2009;
Ferrara et al., 2015
Human ↓ ↑ ↓ Not observed Verge et al., 2012
TRIAC Zebrafish N/R N/R N/R Prevents and
rescues
hypomyelination
Zada et al., 2014, 2016
Mouse ↓ ↓ ↓ Only at high doses
(200–400 ng/g BW)
and early treatment
Kersseboom et al., 2015;
Bárez-López et al., 2016
Human ↓ ↓ ↓ Under Investigation Groeneweg et al., 2019
Sobetirome Mice ↓ ↓ ↓ Modulation of
TH-target genes
Bárez-López et al., 2018
Other therapies Gene replacement
therapy
Zebrafish N/R N/R N/R Rescues
hypomyelination
Zada et al., 2016





Iwayama et al., 2016
Pharmacological
chaperones
In vitro ex vivo N/A N/A N/A N/A Braun and Schweizer,
2015, 2017; Groeneweg
et al., 2018
↑, ↓, = : increased, decreased or not modified, respectively, versus non-treated patients or mouse model; N/R: not reported; N/A: not applicable.
a compensatory mechanism for the lack of MCT8 (Figure 1).
For this reason, two alternative models are currently being
used; MCT8 and DIO2 (Mct8/Dio2KO) or MCT8 and OATP1C1
(Mct8/Slc1c1KO) -deficient mice, in which this compensatory
mechanism is suppressed. These models present a thyroid profile
similar to that of the patients in addition to several neuromotor
alterations, offering a more suitable model (Mayerl et al., 2014;
Bárez-López et al., 2019a).
In addition, other alternative models currently available
include the use of pluripotent stem cells induced from human
patients (Vatine et al., 2017) or the use of other organisms such
as zebrafish (Vatine et al., 2013), chicken (Delbaere et al., 2017) or
even Xenopus (Mughal et al., 2017). For the first time, this rich
cataloge of models is providing the possibility of testing drugs in
a fast and accurate way in preclinical stages in AHDS.
THYROID HORMONE REPLACEMENT
THERAPIES
As soon as it was found that the syndrome was due to
mutations in a transporter of THs, and that it had an endocrine
component with altered THs levels, treatments to intervene
on the thyroid axis were considered. In Mct8KO mice,
the injection of supraphysiological doses of levothyroxine
(LT4) was able to reduce the increased expression of
TRH mRNA in hypothalamic neurons, indicating that in
the absence of MCT8 these neurons can respond to T4
treatment. In contrast, only a high dose of T3 was able to
downregulate TSH levels in plasma with a modest reduction
of TRH, suggesting an impaired uptake of circulating T3
(Trajkovic et al., 2007).
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FIGURE 1 | Proposed model illustrating the differences between MCT8-deficient mice and humans in thyroid hormone availability to neural cells. The model for T3
availability to the brain under normal conditions supports that brain T3 can access the target neural cells though two different routes: (1) directly from the circulation,
with T3 crossing the BBB mainly via the MCT8 transporter into the extracellular fluid where it directly reaches the target neural cells, or (2) T3 can also be produced
locally by DIO2 activity in the astrocytes from T4, which crosses the BBB directly into the astrocytes mainly through MCT8 in humans and through MCT8 and
OATP1C1 in mice. In MCT8-deficient mice, the elevated DIO2 activity in the astrocytes converts the T4 available through OATP1C1 into T3, that is subsequently
available to target neural cells, compensating for the lack of MCT8. In MCT8-deficient humans, this compensatory mechanism cannot take place as OATP1C1 is
hardly present in the human BBB, preventing T4 entry to the brain and its subsequent conversion into T3.
Based on this, in patients, a LT4 supplement alone
or in combination with T3 was initially considered. This
treatment suppressed TSH and restored T4; however, it further
increased T3 serum levels, worsening the hyperthyroidism
in extracerebral tissues, and did not improve the patient’s
neurological impairments (Namba et al., 2008; Papadimitriou
et al., 2008). After this first approximation, a block-replacement
therapy consisting of the administration of propylthiouracil
(PTU; an antithyroid drug that also inhibits type 1 deiodinase
(DIO1), which transforms T4 into T3) together with LT4,
decreased endogenous production of THs and prevented the
conversion of LT4 into T3. This therapy normalized TSH levels
and significantly decreased serum T3, which was reflected in an
improvement in body mass index and a reduction in heart rate.
However, none of the patients experienced any improvement at
the psychomotor level (Wemeau et al., 2008; Visser et al., 2013).
TREATMENT WITH THYROID HORMONE
ANALOGS
The search for T3 analogs that do not require MCT8 to cross the
cell membranes is one of the main strategies in the search for
an effective therapy. 3,5-diiodo-thyropropionic acid (DITPA) is
a T3 analog that binds with similar affinity to the different TR
isoforms, although with much lower affinity than T3 (Pennock
et al., 1992). Despite this, it has been shown to have inotropic
thyromimetic actions but maintaining a low metabolic activity
(Pennock et al., 1992; Moreno et al., 2008). In zebrafish, treatment
with DITPA was able to prevent hypomyelination in Mct8-
deficient embryos but did not fully recovered hypomyelination
present in the larvae (Zada et al., 2014, 2016). The administration
of this compound to MCT8-deficient mice was able to
normalize T3 and TSH while it further decreased T4 levels
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in serum, ameliorating metabolic parameters related to the
hypermetabolism of Mct8KO mice. However, improvements in
brain hypothyroidism could only be observed when using high
doses of DITPA (Di Cosmo et al., 2009; Ferrara et al., 2015). The
administration of DITPA in four patients normalized T3 and TSH
and, unlike in mice, increased the levels of T4 to the lower normal
range in serum, decreasing also the cardiac rhythm. However,
no improvement, or very small, was found in the neurological
performance of these patients when they were assessed with the
Bayley-III scale (Verge et al., 2012).
Another T3 analog that has received special attention is
sobetirome (also called GC-1), a compound that has been
used in numerous animal studies (Hartley et al., 2017) as
well as in clinical trials for patients with dyslipidemias.
Sobetirome binds to TRs with the same affinity for TRβ1 as
T3 but 4–10 times less affinity than T3 for TRα1 (Chiellini
et al., 1998). In 2018 we published the first study evaluating
its action in the absence of MCT8 after intraperitoneal
administration to Mct8/Dio2KO mice (Bárez-López et al.,
2018). An increase in the content of sobetirome was detected
in the brain of the treated animals, demonstrating that it
was able to cross the blood-brain barrier of mice in the
absence of MCT8. Most importantly, we provided evidence of
sobetirome action in brain, regulating the expression of T3
target genes, since it was able to partially recover and even
normalize the expression of some genes that are altered in
Mct8/Dio2KO animals.
A third and promising alternative is 3,5,3’-triiodothyroacetic
acid (TRIAC), a natural metabolite of THs. This compound arises
as one of the potential options for the treatment of patients
since in vitro studies have shown that it can bind the TR with
the same affinity as T3 for the isoform TRα and with greater
affinity for TRβ (Takeda et al., 1995; Messier and Langlois, 2000),
that it can exert thyromimetic actions, and that can access the
inside of the cell in the absence of MCT8 (Horn et al., 2013;
Kersseboom et al., 2015). Moreover, treatment with TRIAC in
zebrafish was able to prevent and rescue hypomyelination in
Mct8-deficient embryos and larvae, respectively (Zada et al.,
2014, 2016). The first study evaluating the in vivo action of
TRIAC in MCT8 deficiency was carried out in Mct8/Slco1c1KO
mice treated with high doses of TRIAC (200-400 ng per gram
of weight per day) during early postnatal stages (from postnatal
day 1 (P1) to P12). These studies revealed that at high doses
TRIAC is able to prevent brain alterations in the absence of
MCT8 (Kersseboom et al., 2015). To get a better understanding
on the potential of this analog in the clinical practice, we assessed
the effects of therapeutic doses of TRIAC at juvenile stages.
Mct8KO mice were treated with of 30 ng of TRIAC per gram
of weight per day (similar to the dose used in patients) in
the drinking water from P21 to P30. This treatment decreased
serum levels of both T3 and T4, improving the peripheral
hyperthyroidism. However, TRIAC content in the brain did not
increase after treatment, and therefore no thyromimetic actions
could be observed in this organ. Moreover, we also found that
the decrease in T4 plasma levels worsened brain hypothyroidism
by further decreasing the brain T3 content and the expression of
some target genes (Bárez-López et al., 2016). This highlights the
importance of considering therapeutic approaches that do not
further decrease serum T4.
Currently, alternative delivery pathways are being explored
in order to increase TRIAC content in the brain with the
final aim of ameliorating the brain hypothyroidism. In a recent
study we administered TRIAC directly into the brain of MCT8-
deficient animals through a catheter inserted into the brain
lateral ventricle (Bárez-López et al., 2019b).We found that this
treatment did not affect T3 or T4 levels in the serum, thus
did not aggravate the brain hypothyroidism. Moreover, even
though TRIAC content increased in the brain after treatment,
this increase was not enough to mediate the expression of T3
target genes. Further studies will be necessary to finally determine
if TRIAC serves as a T3 analog mediating brain effects of
THs in vivo.
Due to the extensive clinical experience with TRIAC, that has
demonstrated its ability to inhibit TSH secretion and therefore
decrease the production of endogenous THs, TRIAC has been
used in a phase I clinical trial evaluating its effectiveness and
safety for treatment of peripheral thyrotoxicosis in MCT8-
deficient patients, both pediatric and adult (Groeneweg et al.,
2019). In accordance with the results found in the animal model,
treatment with 38.3 µg of TRIAC per kg of body weight per
day reduced serum T3 levels to the normal range and further
decreased serum T4 levels. This study has shown that TRIAC
is safe and effective in controlling peripheral thyrotoxicosis
improving the altered weight, heart rate and blood pressure.
However, it is important to point out that reduced plasma T4
levels could have potential adverse consequences on the brain, as
was found in systemically TRIAC-treated Mct8KO mice. Having
evaluated the effects of TRIAC on peripheral thyrotoxicosis and
showing encouraging effects (a trend toward improvement) in
gross motor function when children are treated before 4 year of
age, the clinical study is currently in phase II to evaluate the action
of this analog on neurological symptoms in pediatric patients
(NCT02396459).
OTHER THERAPIES FOR MCT8
DEFICIENCY
In parallel to the use of T3 analogs, other possibilities such as gene
replacement therapy and the use of chemical chaperones are also
currently being explored. In order to improve brain alterations
by gene therapy in mice, MCT8 was administered using adeno-
associated virus (AAV) as a vector with the intention of restoring
MCT8 expression in the brain. For this purpose, AAV9 (which
is transduced in the brain with high efficiency) expressing
MCT8 was injected to MCT8-deficient mice at day P1 either
intravenously or directly into the brain intracerebroventricularly.
The results showed that intravenous administration increased
the content of T3 in the brain and recovered the expression
of T3 target genes altered in MCT8 deficiency. Although
intracerebroventricular administration drove higher expression
of MCT8 in the brain than the intravenous delivery, there
was no increase in the content of T3 or in the expression of
T3 target genes. This could be explained because, unlike the
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intracerebroventricular route, the intravenous delivery was able
to restore MCT8 expression in the choroid plexus demonstrating
that for a successful gene replacement therapy, it is essential
to restore MCT8 in brain barriers to allow entry of THs into
the brain (Iwayama et al., 2016). In zebrafish, the injection
of a genetic construct driving Mct8 expression in vascular
endothelial cells into Mct8-deficient embryos was able to recover
hypomyelination in 10 days post fertilization larvae but not
in 3 days post fertilization embryos. This suggests that genetic
treatment can be beneficial even after brain damage has occurred
and offers a potential treatment for MCT8-deficient patients
(Zada et al., 2016).
A different approximation is the use of pharmacological
chaperones that allow the conformational stabilization of
mutated proteins and assist in their translocation to the
plasma membrane. It is believed that this approach would be
more effective for those mutations in SLC16A2 that affect the
stability of the protein and its intracellular traffic. A recent
work using stable overexpression cell models demonstrated that
the use of pharmacological chaperones can restore MCT8 in
cell membranes and mediate T3 transport in certain types
of SLC16A2 mutations (Braun and Schweizer, 2015, 2017).
However, similar studies have subsequently been carried out
ex vivo on fibroblasts derived from MCT8-deficient patients
without functionally restoring MCT8 in cell membranes,
and thus demonstrating that the ability of pharmacological
chaperones to rescue MCT8 function depends on the cell type
used for the assays (Groeneweg et al., 2018).
CONCLUSION
The complex nature of MCT8 deficiency presents certain
difficulties when designing appropriate therapeutic strategies.
A suitable therapy should ameliorate the peripheral
hyperthyroidism while improving the neurological defects. So far,
several therapeutic approaches have been successful in improving
the peripheral hyperthyroidism in patients. These include a
block-replacement therapy with LT4 in combination with PTU
and the T3 analogs DITPA and TRIAC. Treatment with TRIAC
further decreases T4 serum levels unlike DITPA and LT4 + PTU
treatments. Due to the potential effects that T4 (through local
conversion into T3) might be mediating in the brain, an ultimate
therapeutic approach should not further decrease but restore
serum T4 levels.
The big challenge ahead of us is the improvement of the
neurological alterations in patients. To tackle this, several
approaches that aim to overcome the limitation of the brain
barriers are currently being explored. The use of alternative
delivery pathways that can increase the content of T3 analogs
in the brain offers the possibility of enhancing the potential
action of these analogs in the brain, as long as they are indeed
effective in mediating TH-like actions in vivo. The use of
the sobetirome, gene replacement therapy and pharmaceutical
chaperones offers promising alternative therapies that require
further characterization. Moreover, as an early treatment is
crucial, the use of T3 analogs that can cross the placental
barrier such as TRIAC (Nicolini et al., 1996) or DITPA (Ferrara
et al., 2014) or the direct in utero administration of potential
therapeutic agents, must be considered.
Due to the great advances in preclinical stages of potential
therapies for AHDS, we believe that studies devoted to enhance
our understanding about the role of MCT8 in development
and the complex changes in the CNS related with this disorder
are particularly urgent in order to proceed with an optimal
translation of the different therapeutic approaches to patients.
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